SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
几米杨
Lv2
200 积分
2022-12-01 加入
最近求助
最近应助
互助留言
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
7天前
已完结
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
7天前
已完结
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
7天前
已完结
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes
7天前
已完结
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
7天前
已完结
Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?
8天前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
8天前
已完结
Efficacy and Safety of Tirzepatide versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
14天前
已完结
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
14天前
已完结
Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
1个月前
已完结
没有进行任何应助
速度真快
14天前
速度真快
14天前
帮大忙了
2个月前
速度真快
3个月前
速度真快
3个月前
速度真快
3个月前
速度真快
3个月前
找到了【积分已退回】
4个月前
么么哒
5个月前
点赞
5个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论